IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6520
EU - Europa 892
AS - Asia 180
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 7596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6517
SE - Svezia 241
IE - Irlanda 178
SG - Singapore 138
IT - Italia 130
DE - Germania 115
UA - Ucraina 114
GB - Regno Unito 36
CN - Cina 26
BE - Belgio 17
FR - Francia 14
DK - Danimarca 10
FI - Finlandia 8
KR - Corea 7
RO - Romania 7
JP - Giappone 4
BG - Bulgaria 3
NL - Olanda 3
RU - Federazione Russa 3
AU - Australia 2
CA - Canada 2
ES - Italia 2
IL - Israele 2
LU - Lussemburgo 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IN - India 1
IS - Islanda 1
LI - Liechtenstein 1
MX - Messico 1
PL - Polonia 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7596
Salva come PNG Salva come JPEG
Città #
Des Moines 1470
Chandler 1178
Fairfield 666
Wilmington 345
Ashburn 304
Woodbridge 282
Houston 249
Seattle 229
Cambridge 214
Jacksonville 199
Dublin 170
Lawrence 167
Princeton 167
San Mateo 142
Ann Arbor 135
San Diego 100
Redmond 72
Falls Church 31
London 25
Norwalk 19
Ancona 17
Brussels 17
Beijing 15
Forlì 9
Centro 8
Helsinki 8
Strasbourg 7
Menlo Park 6
Boydton 5
Marche 5
Nanjing 5
Rome 5
Canosa di Puglia 4
Redwood City 4
Stockholm 4
Pesaro 3
Portland 3
Saint Petersburg 3
Sofia 3
Torre Del Greco 3
Amsterdam 2
Appignano 2
Augusta 2
Boardman 2
Campobasso 2
Civitanova Marche 2
Frankfurt am Main 2
Fuzhou 2
Kagoya 2
Los Angeles 2
Macerata 2
Madrid 2
Montelupone 2
Montreal 2
Ostra Vetere 2
San Benedetto del Tronto 2
San Costanzo 2
Slobozia 2
Sydney 2
Tel Aviv 2
Trecate 2
Barbara 1
Belgrade 1
Borca 1
Borås 1
Bucharest 1
Budapest 1
Castelfidardo 1
Castelraimondo 1
Chicago 1
Dubai 1
Falconara Marittima 1
Galati 1
Glasgow 1
Hanover 1
Hebei 1
Hefei 1
Jakarta 1
Jesi 1
Keflavik 1
Kunming 1
Lecco 1
Luxembourg 1
Milan 1
Montegranaro 1
North Kingstown 1
Ostra 1
Phoenix 1
Prague 1
Schaan 1
Secaucus 1
Settimo Milanese 1
Squinzano 1
São Paulo 1
Teramo 1
Tokyo 1
Torino 1
Turin 1
Valeggio Sul Mincio 1
Vallefoglia 1
Totale 6379
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 135
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 113
Immunotherapy in genitourinary cancers: Where are we going? 101
Are liver nested stromal epithelial tumors always low aggressive? 95
From undergraduate medical school student to visible pathologist 83
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 81
Microbiome and cancers, with focus on genitourinary tumors 76
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 72
Molecular diagnostics in uro-oncology 71
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 71
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 71
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 70
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 68
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 68
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 68
Pd-l1 inhibitors for the treatment of prostate cancer 67
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 66
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 65
Exploring the Spectrum of Kidney Ciliopathies 65
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 64
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 64
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 63
The human microbiota and prostate cancer: Friend or foe? 63
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 63
Is There a Role for Immunotherapy in Prostate Cancer? 63
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 61
Epigenetic modifications and modulators in prostate cancer 60
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 60
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 60
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 59
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 59
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 58
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 58
Predicting future cancer burden in the United States by artificial neural networks 58
Molecular characterization of testicular germ cell tumors using tissue microdissection 58
Quick steps toward precision medicine in renal cell carcinoma 58
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 58
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 58
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 57
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 57
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 56
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 56
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 56
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 56
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 55
Emerging molecular technologies in genitourinary tumors 55
Pathology without microscope: From a projection screen to a virtual slide 55
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 55
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 54
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 54
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 54
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 54
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 53
Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges 53
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 53
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 53
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 53
Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: A narrative review 53
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 53
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 52
The identification of immunological biomarkers in kidney cancers 52
Immunotherapy and radiation therapy in renal cell carcinoma 52
An update on investigational therapies that target STAT3 for the treatment of cancer 52
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 51
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 51
Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? 51
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 51
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 51
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 51
Emerging molecular technologies in renal cell carcinoma: Liquid biopsy 50
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now 50
Treating prostate cancer by antibody-drug conjugates 50
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 49
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 49
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 49
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 49
Immune checkpoint inhibitors for the treatment of bladder cancer 49
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 48
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 48
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 48
Whole slide imaging of large format histology in prostate pathology: Potential for information fusion 47
Editorial: Emerging biomarkers in genitourinary tumors 47
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 47
Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656–61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists 46
Narrative review: Update on immunotherapy and pathological features in patients with bladder cancer 46
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 46
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 45
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 45
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 45
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 45
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 44
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 44
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 44
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 44
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 44
Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560–9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? 44
Variants of Bladder Cancer: The Pathologist's Point of View 44
Renal Cell Carcinoma: genomic landscape and clinical implications 44
Pd-l1 testing for urothelial carcinoma: Interchangeability, reliability and future perspectives 44
Molecular Pathology of Urothelial Carcinoma 44
Totale 5748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201812 0000 00 00 6510
2018/201932 10004 07 01 1513
2019/2020151 2070 164 152 21113142
2020/20212174 38406863 224762 182186 13820023043
2021/20221512 2671717923 50179 2890 12811687294
2022/20233899 266288156313 2181705 5240 708000
Totale 7791